Asset profile

Ganagliflozin

Small molecule

Sodium-glucose cotransporter 2 (SGLT2)No featureable registry evidence
Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
—no evidence

Evidence outlook

No featureable registry evidence

The studies registered under this drug are withdrawn, terminated, post-marketing only, or belong to other products, so none can represent its own clinical progression.

How the evidence outlook works ↗

Competitive landscape

61 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 61 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ganagliflozin: this drugNot yet studiedSmall moleculeSodium-glucose cotransporter 2 (SGLT2)
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2), DPP-4
Atrasentan (Vanrafia)ApprovedSmall moleculeEndothelin A receptor
Avacopan (Tavneos)ApprovedSmall moleculeComplement C5a receptor 1 (C5aR1/CD88)
Baxdrostat (Baxfendy)ApprovedSmall moleculeAldosterone synthase (CYP11B2)
Budesonide (targeted-Release) (TARPEYO / Nefecon)ApprovedSmall moleculeGlucocorticoid receptor
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2
Daprodustat (Jesduvroq)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cells
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriol
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletion
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletion
Ferric Pyrophosphate Citrate (Triferic)ApprovedSmall moleculeIron-replacement therapy delivered via dialysate

…and 46 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (1)
December 2027 (1)
Phase 4T2DM (Type 2 Diabetes Mellitus)Recruiting
Est. primary completion 2027-12-31 · NCT07244003 · CT.gov ↗
What to watch
Unlock with Research ↗
2031 (1)
October 2031 (1)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2031-10-30 · NCT07116928 · CT.gov ↗
What to watch
Unlock with Research ↗

See the full readout calendar ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.

Phase 4 (2)